Nutrient Density for Everyone: The Bigger Lesson From GLP-1 Medications

This week at Vitafoods Europe in Barcelona, the trade press carried a headline that was easy to miss but worth pausing on: “Nutrient density for everyone: the bigger GLP-1 opportunity.” The framing matters. It treats the GLP-1 boom not as a niche pharmaceutical story but as a lens through which a much older problem becomes visible. People taking semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) eat less, sometimes substantially less, and when total food intake drops, what is in each bite becomes a more serious question than how many bites there are.

The numbers behind the framing are, if anything, sharper than the framing itself.

What the 2026 research actually says

In February 2026, a research team led by Jorge Urbina published a narrative review in Clinical Obesity (Wiley) synthesizing six studies of GLP-1 users, covering 480,825 adults in total. The review followed structured PRISMA-ScR methodology and is the most current systematic look at nutritional outcomes during GLP-1 therapy. The headline finding: 12.7% of GLP-1 users were newly diagnosed with a nutritional deficiency within six months of starting therapy, rising to 22.4% within twelve months ¹.

Vitamin D deficiency was the most common, affecting 7.5% of users at six months and 13.6% at twelve months. Iron status was meaningfully worse than in matched comparators: GLP-1 users showed 26 to 30% lower ferritin levels than people taking SGLT2 inhibitors for similar metabolic conditions. More than 60% of GLP-1 users consumed below estimated requirements for calcium and iron, and average vitamin D intake reached only about 20% of recommended levels.

The review is careful about what these numbers mean. The authors note that the findings come largely from observational datasets and that causality between GLP-1 use and deficiencies cannot be definitively established from this evidence alone. The mechanism is, however, plausible and easy to describe: appetite suppression, delayed gastric emptying, and altered absorption combine to reduce both the volume and the nutrient yield of food intake.

There is a second, equally important finding from the same body of evidence. Clinical trials of GLP-1 medications report that lean mass loss accounts for a meaningful fraction of total weight lost, often in the 25 to 40% range, with the STEP-1 trial of semaglutide showing 45.2% of weight lost coming from lean mass and the SURMOUNT-1 trial of tirzepatide showing 25.7% ². Muscle preservation depends heavily on adequate protein, resistance training, and overall nutrient status. The deficiency story and the muscle story are the same story told from two angles.

The bigger lesson is not about GLP-1 users

Here is where the Vitafoods framing earns its keep. If you assume European adults eating a typical European diet are starting from a position of nutritional sufficiency, then the GLP-1 deficiency findings look like a drug side effect. They look exceptional. The data does not support that assumption.

The European Food Safety Authority recommends a daily fiber intake of at least 25 grams for adults, a figure set in its 2010 dietary reference values opinion ³. The German Nutrition Society (DGE) recommends a minimum of 30 grams per day, a position retained in the most recent D-A-CH reference value update. The UK’s Scientific Advisory Committee on Nutrition set a 30 gram target in 2015. France’s ANSES advises around 30 grams. (For a side-by-side of EU and US guidelines, see how much fiber per day.) Average European intake, across multiple national surveys, sits at 16 to 24 grams per day for men and 16 to 20 grams per day for women, with little variation between countries ⁴. Most European adults miss even the 25 gram EFSA floor — a structural deficit we map in detail in the European fiber gap. The national 30 gram targets are missed by a larger margin still.

It follows, almost as arithmetic, that GLP-1 users (whose total food intake is meaningfully reduced) sit substantially further below recommended fiber intake than the European average. The clinical deficiency numbers reported in the Urbina review are not surprising once the population baseline is taken into account. They are what happens when a structurally inadequate diet is then made smaller.

The category framing of “GLP-1 companion nutrition” is, on this reading, slightly off. The product opportunity is not unique to GLP-1 users. The opportunity is that GLP-1 users are visibly experiencing, in compressed form, the same nutritional density deficit that quietly affects most of the population already.

What “nutrient density per bite” actually means

The phrase is more concrete than it sounds. For any given calorie of food, you can ask: how much protein, how much fiber, how many micronutrients did that calorie deliver?

A bowl of refined-flour pasta delivers calories with very little of any of the above. A bowl of lentils delivers comparable calories alongside roughly 16 grams of fiber, 18 grams of protein, and a meaningful share of daily iron and folate. The two bowls look similar on a plate. They are not similar nutritionally. When a person eats four full meals a day, the difference between the two bowls is partly absorbed by overall volume. When a person eats two small meals a day (as many GLP-1 users do during titration, and as many older adults do simply because appetite changes with age) the difference between the two bowls is the difference between meeting daily requirements and not.

The same logic explains why fiber matters disproportionately in this context. Fiber-rich foods tend to be nutrient-dense by default: legumes, intact whole grains, vegetables, fruits with skins, nuts, and seeds carry their fiber alongside protein, micronutrients, and beneficial phytochemicals. Highly processed foods do the opposite. They concentrate calories while stripping out everything else. “Eat more fiber” is therefore, in practice, a useful shorthand for “eat more nutrient-dense food.”

For GLP-1 users specifically, there is a second layer. Constipation is the most commonly reported gastrointestinal side effect of GLP-1 therapy, affecting a substantial share of users at therapeutic doses. The underlying mechanism is delayed gastric emptying and reduced motility. Adequate fiber and adequate fluid both help. For users who cannot reach fiber targets through food (because total food intake has dropped) a supplement is a reasonable consideration — and the 4-week ramp-up protocol we publish covers how to introduce one without bloating. The same is not necessarily true for the wider population, where food-first is generally the better starting point.

What this changes about how we think about supplements

The default assumption in supplement marketing is that pills and powders are for filling deficiencies. The Vitafoods reframe is sharper: supplements (and reformulated functional foods) are for the case where the food itself cannot do the job. That case is acute among GLP-1 users. It is real among older adults with reduced appetite. It is real among people in stressful life phases who undereat without meaning to. It is real among shift workers, athletes during cutting phases, and people in recovery from illness. None of these groups are exotic. Combined, they are a meaningful share of any European population.

The corollary is that the question to ask of any nutrient-density product is not “does this target GLP-1 users?” It is “does this deliver real density per serving, and is it for someone whose food intake will not deliver that density on its own?” The first question is marketing. The second question is editorial.

For the full picture on fiber and GLP-1 medications, see our complete guide to fiber and GLP-1.